Background
Phase III RCT (MAGIC). 503 patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus randomized 1:1 to perioperative ECF chemotherapy plus surgery vs surgery alone. Approximately 26% had lower esophageal/junction primaries; 74% had gastric primaries.
Interventions and follow up
Arm A: ECF — epirubicin 50 mg/m² + cisplatin 60 mg/m² on day 1 + continuous IV 5-FU 200 mg/m²/day × 21 days; 3 preoperative cycles + 3 postoperative cycles
Arm B: Surgery alone
Primary endpoint: Overall survival
Median follow-up: ~4 years
Arm B: Surgery alone
Primary endpoint: Overall survival
Median follow-up: ~4 years
Results
OS: HR 0.75 (95% CI 0.60–0.93), P=.009; 5-year OS 36% vs 23%
PFS: HR 0.66 (95% CI 0.53–0.81), P<.001
Pathologic downstaging: Tumors significantly smaller and less advanced in the perioperative arm (pT1/2: 52% vs 37%)
PFS: HR 0.66 (95% CI 0.53–0.81), P<.001
Pathologic downstaging: Tumors significantly smaller and less advanced in the perioperative arm (pT1/2: 52% vs 37%)
Adverse events
Surgical: Postoperative complications similar (46% vs 45%); no significant increase in postoperative mortality with perioperative chemotherapy.
Chemotherapy-related: Grade 3/4 neutropenia, nausea, and alopecia in the ECF arm.
Chemotherapy-related: Grade 3/4 neutropenia, nausea, and alopecia in the ECF arm.
Conclusions
Perioperative ECF chemotherapy significantly improved OS (HR 0.75) and PFS compared to surgery alone in resectable gastric and lower esophageal/junction adenocarcinoma, establishing perioperative chemotherapy as a standard-of-care option in Western patients.
Key Limitations
Key Limitations: The ECF regimen (requiring continuous IV 5-FU pump) has since been superseded by FLOT (FLOT4 trial) based on OS superiority. Only 42% of patients completed all 6 chemotherapy cycles (especially postoperative cycles). The trial did not mandate D2 dissection — lymph node dissection extent was suboptimal by current standards. The 74% gastric predominance limits direct application to GEJ primaries.
Clinical Context
MAGIC established the perioperative chemotherapy paradigm for resectable gastric/GEJ cancer in Europe and was practice-changing. FLOT4 subsequently demonstrated OS superiority of FLOT over ECF/ECX (50 vs 35 months), making FLOT the current perioperative standard per ASCO and ESMO guidance. INT-0116 (postoperative chemoradiotherapy) remains an option in the US, particularly after inadequate nodal dissection.
References
References: Cunningham D et al, N Engl J Med 2006 (MAGIC)